H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Panbela Therapeutics (PBLA – Research Report) today and set a price target of $16.00. The company’s shares opened today at $7.36.
Pantginis covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, Tempest Therapeutics, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of 6.6% and a 45.58% success rate on recommended stocks.
Currently, the analyst consensus on Panbela Therapeutics is a Moderate Buy with an average price target of $8.75.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $1,680.00 and a one-year low of $5.00. Currently, Panbela Therapeutics has an average volume of 117.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sun BioPharma Inc. is a clinical-stage drug development company, which engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Read More on PBLA:
- Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
- Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
- Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
- Panbela Provides Business Update and Reports Q1 2023 Financial Results
- Panbela Therapeutics initiated with a Buy at H.C. Wainwright
